COMSTOCK ANNOUNCES SECOND QUARTER 2026 BUSINESS RESULTS AND OUTLOOK

Comstock Inc. (LODE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_992178.htm EXHIBIT 99.1 ex_992178.htm Exhibit 99.1 NEWS RELEASE COMSTOCK ANNOUNCES SECOND QUARTER 2026 BUSINESS RESULTS AND OUTLOOK VIRGINIA CITY, NEVADA, July 23, 2026 – Comstock Inc. (NYSE: LODE) (“Comstock,” “our,” and the “Company”), today announced its second qu

Original reporting
Published Jul 24, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LODE
Neutral
medium confidence
Mentioned
$LODE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LODENeutralMed
01

Why it matters

Key trading drivers are (1) the expected August 2026 closing of legacy mining asset sale for over $45M, (2) a $16.4M impairment tied to Bioleum technology realignment, and (3) liquidity/capital actions including extinguishing promissory notes and increasing investment in Sierra Springs Opportunity Fund.

02

Market read

This is a primary 8-K with concrete deal terms, impairment magnitude, and operational milestones, which can drive valuation and risk perception into the August closing window.

03

What to watch

Closing is subject to TSX-V clearance, and the $10M contingent payment plus retained NSR royalty introduce execution and commodity-price sensitivity that could affect valuation into August.

Relevance 7/10Novelty 7/10Timing: after-hours filing of Q2 2026 results and outlook, with August 2026 closing timeline

Background

Comstock filed an 8-K with an exhibit covering Q2 2026 results, operational commissioning progress for its recycling/upgrading business, a planned sale of legacy mining assets, and a Bioleum technology impairment.

Company-level read

Ticker impact

$LODENeutralMedium confidence
Context

Comstock reported Q2 2026 results and outlook, including a planned August 2026 sale of legacy mining assets for over $45M.

Expected impact

Likely choppy reaction with downside risk from the $16.4M impairment offset by reduced legacy-asset risk and clearer August closing cash proceeds.

Evidence & confidence

The filing is a primary disclosure (8-K with exhibit) and includes concrete transaction terms (consideration, timing, contingent payment) plus a sizable non-cash impairment and capital reallocation.

Market effects

Highlights ongoing restructuring in metals recycling and legacy mining portfolios, with emphasis on commissioning timelines and offtake upgrades.

JobsOhio grant and Cambridge, OH facility plans reinforce regional renewable supply-chain investment narratives.

Limited direct global read-across; more relevant to US end-of-life solar panel recycling and critical metals recovery supply chains.

Counterpoint

The impairment is largely non-cash, so the market may over-discount the balance-sheet impact while underweighting the operational ramp and asset-sale cash proceeds.

Key entities

  • Comstock Inc.

    NYSE-listed company (LODE) reporting Q2 2026 results and outlook, including legacy asset sale and Bioleum impairment.

  • Mackay Precious Metals Inc.

    Buyer in the planned August 2026 sale of Comstock legacy mining assets, with cash/stock consideration and retained NSR royalty.

  • Bioleum Corporation

    Renewable fuels business within Comstock that recorded a $16.4M impairment after realigning technology paths.

  • Sierra Springs Opportunity Fund Inc.

    Comstock increased ownership to 47.63%, funding land and water-right acquisitions and related monetization plans.

Related articles

$LODEMed

COMSTOCK REPORTS THIRD QUARTER 2026 RESULTS

Comstock Inc. (LODE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE COMSTOCK REPORTS THIRD QUARTER 2026 RESULTS SOLAR RECYCLING UNDERWAY; MINE SALE GAIN; SSOF MONETIZATION; BUYBACK AUTHORIZED RENO, NEVADA, November 4, 2026 - Comstock Inc. (NYSE American: LODE) (“Comstock,” “we,” “our,” and the “Company”), today announced

$LODEMedAI 8/10

2026 - 06 - 22 | Comstock Sells Legacy Mining Assets to Mackay Precious Metals Inc. | NYSEAM: LODE

Comstock Inc. (NYSE: LODE) said it signed a Securities Purchase Agreement to sell 100% of certain mineral and mining real estate entities to Mackay Precious Metals Inc., a Mackay Gold & Silver subsidiary, for over $45 million. Terms include $30+ million in cash/stock, a retained 1.5% NSR royalty, assumption of reclamation obligations, and a $10 million contingent payment. Comstock expects $1.5 million annualized cost savings.

$MRCYMed

Mercury Systems 3Q 2026: Revenue $253.15M, EPS $0.21 — 10-Q Summary

Mercury Systems reported 3Q 2026 revenue of $253.15M, up 12.4% YoY, and net income of $13.09M, reversing a prior-year loss. Growth in radar and electronic warfare applications drove results, while C4I revenue declined. Gross margin improved to 35.2% from 27.9%. The company expects to recognize 46% of its $1.193B remaining performance obligations as revenue in the next 12 months.

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$CPIXHighAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland

$ATROHighAI 8/10

Astronics shares tumble on soft fourth quarter revenue outlook

Astronics (ATRO) reported Q3 earnings of $1.08 per share, beating estimates, with revenue up 28.5% YoY to $271.7M. However, shares fell 11% on Q4 revenue guidance of $255M-$275M, below expectations. The company maintained its full-year 2026 revenue guidance. Aerospace segment sales hit a record $245.5M, with strong demand in inflight entertainment and connectivity.